Type 2 diabetes in patients with end-stage renal disease is not associated with further increased serum inflammatory parameters

Journal of Nephrology

Volumn 17, Issue 1, 2004, Pages 112-117

  Bodlaj, Gerd ^a   Berg, Jörg ^a   Pichler, Robert ^a   Sailer, Thomas ^b   Biesenbach, Georg ^a  

^a KEPLER UNIVERSITY HOSPITAL   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atherosclerosis; Diabetes; End stage renal disease; Hemodialysis; Inflammation

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6; NEOPTERIN; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS; HUMAN; INFLAMMATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; SAMPLE SIZE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ARTERIOSCLEROSIS; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NEOPTERIN; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RENAL DIALYSIS;

EID: 1842450546     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Lazarus JM, Lowrie EG, Hampers CL, Merrill JP. Cardiovascular disease in uremic patients on hemodialysis. Kidney Int 1975; 2: 167-75.
2. Mailloux LU. Hypertension in chronic renal failure and ESRD: prevalence, pathophysiology, and outcomes. Semin Nephrol 2001; 21: 146-56.
3. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study. Kidney Int 1999; 55: 1945-51.
4. Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial 2000; 13: 4-8.
5. Kaysen GA. Hyperlipidemia of chronic renal failure. Blood Purif 1994; 12: 60-7.
6. Bostom AG, Shemin D, Lapane KL, Sutherland P, Nadeau MR, Wilson PW, Yoburn D, Bausserman L, Tofler G, Jacques PF, Selhub J, Rosenberg IH. Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein(a) excess in maintenance dialysis patients: A matched case-control study. Atherosclerosis 1996; 125: 91-101.
7. Chugh SN, Jain S, Agrawal N, Sharma A. Evaluation of oxidative stress before and after haemodialysis in chronic renal failure. J Assoc Physicians India 2000; 48: 981-4.
8. Asanuma K, Yokoyama K, Tsukada T, Takemoto F, Hara S, Yamada A, Tomino Y. An intron 4 gene polymorphism in endothelial cell nitric oxide synthase might modulate lipid metabolism in nondiabetic patients on hemodialysis. Nephron 2001; 88: 39-43.
9. Weissberg PL, Bennett MR. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
10. Sakkinen P, Abbott RD, Curb JD, Rodriguez BL, Yano K, Tracy RP. C-reactive protein and myocardial infarction. J Clin Epidemiol 2002; 55: 445-51.
11. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72.
12. Elkind MS, Cheng J, Boden-Albala B, Rundek T, Thomas J, Chen H, Rabbani LE, Sacco RL. Tumor necrosis factor receptor levels are associated with carotid atherosclerosis. Stroke 2002; 33: 31-7.
13. Gurfinkel EP, Scirica BM, Bozovich G, Macchia A, Manos E, Mautner B. Serum neopterin levels and the angiographic extent of coronary arterial narrowing in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol 1999; 83: 515-8.
14. Zoccali C, Mallamaci F, Tripepi G. Inflammation and atherosclerosis in end-stage renal disease. Blood Purif 2003; 21: 29-36.
15. Rattazzi M, Puato M, Faggin E, Bertipaglia B, Grego F, Pauletto P. New markers of accelerated atherosclerosis in end-stage renal disease. J Nephrol 2003; 16: 11-20.
16. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002; 17: 1684-8.
17. Chantrel F, Enache I, Bouiller M, Kolb I, Kunz K, Petitjean P, Moulin B, Hannedouche T. Abysmal prognosis of patients with type 2 diabetes entering dialysis. Nephrol Dial Transplant 1999; 14: 129-36.
18. Altman JJ, Elian N, Grun S, Gerard HG, Feldman S. The outcome of advanced chronic nephropathy in type 1 and type 2 diabetic and non-diabetic patients: A prospective study. Diabetes Metab 1999; 25: 144-9.
19. Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 2002; 23: 831-4.
20. Palareti G, Maccaferri M. Specific assays of hemostasis proteins: Fibrinogen. Ric Clin Lab 1990; 20: 167-76.
21. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289: 2560-72.
22. Schwedler S, Schinzel R, Vaith P, Wanner C. Inflammation and advanced glycation end products in uremia: Simple co-existence, potentation or causal relationship. Kidney Int 2001; 78 (suppl 1): S32-6.
23. Descamps-Latscha B, Herbelin A, Nguyen AT, Roux-Lombard P, Zingraff J, Moynot A, Verger C, Dahmane D, de Groote D, Jungers P. Balance between IL-1β, TNF-α, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationship with activation markers of T-cells, B cells and monocytes. J Immunol 1995; 154: 882-92.
24. Ramanathan M. A physicochemical modelling approach for estimating the stability of soluble receptor-bound tumor necrosis factor-alpha. Cytokine 1997; 9: 19-26.
25. Berdowska A, Zwirska-Korczala K. Neopterin measurement in clinical diagnosis. J Clin Pharm Ther 2001; 26: 319-29.
26. Yokoyama K, Tajima M, Yoshida H, Nakayama M, Tokutome G, Sakagami H, Hosoya T. Plasma pteridine concentrations in patients with chronic renal failure. Nephrol Dial Transplant 2002; 17: 1032-6.
27. Zaoui P, Hakim RM. The effects of the dialysis membrane on cytokine release. J Am Soc Nephrol 1994; 4: 1711-8.
28. Pereira BJ, Snodgrass BR, Hogan PJ, King AJ. Diffuse and convective transfer of cytokine-inducing bacterial products across hemodialysis membranes. Kidney Int 1995; 47: 603-10.
29. Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumor necrosis factor α and blood cytokine production in type 2 diabetes. Life Sci 2000; 67: 291-300.
30. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-58.
31. Don BR, Kaysen GA. Assessment of inflammation and nutrition in patients with end-stage renal disease. J Nephrol 2000; 13: 249-59.
32. Stenvinkel P, Wanner C, Metzger T, Heimbürger O, Mallamaci F, Tripepi G, Malatino L, Zoccali C. Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage? Kidney Int 2002; 62: 1791-8.
33. Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-911.